Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 17
2003 11
2004 9
2005 14
2006 19
2007 15
2008 24
2009 29
2010 20
2011 19
2012 23
2013 26
2014 13
2015 15
2016 13
2017 10
2018 15
2019 5
2020 15
2021 17
2022 14
2023 28
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

320 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.
Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J; STOP-IgAN Investigators. Rauen T, et al. N Engl J Med. 2015 Dec 3;373(23):2225-36. doi: 10.1056/NEJMoa1415463. N Engl J Med. 2015. PMID: 26630142 Free article. Clinical Trial.
Nephroprotective Properties of Antidiabetic Drugs.
Gerdes C, Müller N, Wolf G, Busch M. Gerdes C, et al. Among authors: wolf g. J Clin Med. 2023 May 10;12(10):3377. doi: 10.3390/jcm12103377. J Clin Med. 2023. PMID: 37240483 Free PMC article. Review.
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Budde K, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J; STOP-IgAN Investigators. Rauen T, et al. Kidney Int. 2020 Oct;98(4):1044-1052. doi: 10.1016/j.kint.2020.04.046. Epub 2020 May 22. Kidney Int. 2020. PMID: 32450154 Clinical Trial.
The eye, the kidney and microcirculation.
Blum M, Saemann A, Wolf G. Blum M, et al. Among authors: wolf g. Nephrol Dial Transplant. 2011 Jan;26(1):4-6. doi: 10.1093/ndt/gfq425. Epub 2010 Jul 13. Nephrol Dial Transplant. 2011. PMID: 20628181 No abstract available.
Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort.
Reimer KC, Nadal J, Meiselbach H, Schmid M, Schultheiss UT, Kotsis F, Stockmann H, Friedrich N, Nauck M, Krane V, Eckardt KU, Schneider MP, Kramann R, Floege J, Saritas T; GCKD study investigators. Reimer KC, et al. Bone Res. 2023 Oct 20;11(1):52. doi: 10.1038/s41413-023-00291-8. Bone Res. 2023. PMID: 37857629 Free PMC article.
Adipokines promote chronic kidney disease.
Rüster C, Wolf G. Rüster C, et al. Among authors: wolf g. Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv8-14. doi: 10.1093/ndt/gft191. Nephrol Dial Transplant. 2013. PMID: 24179016 Review.
Role of Neuropilin-1 in Diabetic Nephropathy.
Bondeva T, Wolf G. Bondeva T, et al. Among authors: wolf g. J Clin Med. 2015 Jun 17;4(6):1293-311. doi: 10.3390/jcm4061293. J Clin Med. 2015. PMID: 26239560 Free PMC article. Review.
320 results